Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241604 | 1.00 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL18415628 | 0.78 | CYP19A1 (0.61) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL7294129 | 0.78 | CYP19A1 (0.56) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL28540353 | 0.78 | MAOA (0.53) | CYP19A1MAOB | |
| SCHEMBL768947 | 0.77 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL15147097 | 0.77 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL2381366 | 0.77 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL20165977 | 0.77 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL14395262 | 0.77 | CYP19A1 (0.42) | CYP19A1MAOBPKMTSHR | |
| SCHEMBL6592452 | 0.77 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022165402-A1 | INHIBITORS OF PROTEIN KINASE A | BLUEPRINT MEDICINES CORPORATION (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20170022165-A1 | PQSR MODULATORS | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2017-01-26 | — | — | US | disclosed |
| US-9211725-B2 | Inkjet recording method and printed material | FUJIFILM CORPORATION (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9211725-B2 | Inkjet recording method and printed material | FUJIFILM CORPORATION (JP) | 2015-12-15 | — | — | US | disclosed |
| EP-2682272-B1 | INK JET RECORDING METHOD AND PRINTED MATERIAL | FUJIFILM CORP (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20140206682-A1 | COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| US-20140206682-A1 | COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| US-20140206682-A1 | COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2751107-A1 | COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033620-A1 | COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20080182031-A1 | Sensitizing dye, an alpha-aminoketone or acyl phosphine oxide polymerization initiator and an ethylenically unsaturated bond-containing polymerizable compound | FUJIFILM CORPORATION (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080182031-A1 | Sensitizing dye, an alpha-aminoketone or acyl phosphine oxide polymerization initiator and an ethylenically unsaturated bond-containing polymerizable compound | FUJIFILM CORPORATION (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1944173-A1 | Ink composition and inkjet recording method using the same | FUJIFILM Corporation (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1885708-A2 | GPCR MODULATORS | Board of Trustees of Michigan State University (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1877093-A2 | ASCORBATE BINDING PEPTIDES | Board of Trustees of Michigan State University (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006113557-A2 | GPCR MODULATORS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006113602-A2 | ASCORBATE BINDING PEPTIDES | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-6531617-B2 | Adding an acid halide to a solution of aluminum chloride to form an alkylcarbonyloxy chromanone, which is further reacted with lithium (hydro)peroxide at a temperature of < 0 degrees C | MERCK & CO., INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020095047-A1 | Process for preparing hydroxychomanones and CIS-aminochromanols | MERCK & CO., INC. | 2002-07-18 | — | — | US | disclosed |
| CN-1334720-A | Cosmetic skin care compositions contg 4-chromanone | UNILEVER NV (NL) | 2002-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206682-A1 | COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS | PDGFRA, PDGFRB, PDGFA | CYP19A1 2495/4885MAOB 2714/4885PKM 378/4885 |
| US-20170022165-A1 | PQSR MODULATORS | QARS1, SRPRA, MRPS35 | CYP19A1 3517/4885MAOB 3937/4885PKM 1619/4885 |
| US-20020095047-A1 | Process for preparing hydroxychomanones and CIS-aminochromanols | HACL2, HAAO, APEH | CYP19A1 158/4885MAOB 290/4885PKM 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.